Summary of Study ST002153

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001366. The data can be accessed directly via it's Project DOI: 10.21228/M85115 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST002153
Study TitleData from plasma metabolome analysis of APP-KI and Wild type mice treated with B. breve MCC1274
Study SummaryRecently, we showed that administration of B. breve MCC1274 reduced amyloid-beta production, inhibited microglial activation, and suppressed inflammatory responses in the brains of APP knock-in (AppNL-G-F) mice. To elucidate the mechanism of action of this probiotic strain in an Alzheimer's disease-like model, we orally fed 3-month-old mice with B. breve MCC1274 or saline for 4 months and comprehensively investigated metabolites in plasma using CE-FTMS and LC-TOFMS.
Institute
Morinaga milk industry CO., LTD.
DepartmentNext generation science institute
LaboratoryFrontier research section
Last NameOhno
First NameKazuya
Address1-83 5-Chome Higashihara, Zama-city, Kanagawa-Pref. Japan
Emailkazuya-oono443@morinagamilk.co.jp
Phone81462523067
Submit Date2022-04-18
Analysis Type DetailLC-MS
Release Date2022-10-03
Release Version1
Kazuya Ohno Kazuya Ohno
https://dx.doi.org/10.21228/M85115
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR001366
Project DOI:doi: 10.21228/M85115
Project Title:Improvement of cognitive function by B. breve MCC1274 and elucidation of its mechanism of action
Project Summary:Although many studies have suggested that probiotics could modulate various brain functions via the gut-brain axis, little is known about the mechanism underlying this process. We previously reported the beneficial effects of a probiotic strain, Bifidobacterium breve MCC1274, on cognitive function in preclinical and clinical studies. Recently, we showed that administration of this strain reduced amyloid-beta production, inhibited microglial activation, and suppressed inflammatory responses in the brains of APP knock-in (AppNL-G-F) mice. To elucidate the mechanism of action of this probiotic strain in an Alzheimer's disease-like model, we orally fed 3-month-old mice with B. breve MCC1274 or saline for 4 months and comprehensively investigated metabolites in plasma using CE-FTMS and LC-TOFMS.
Institute:Morinaga milk industry CO., LTD.
Department:Next generation science institute
Laboratory:Frontier research section
Last Name:Ohno
First Name:Kazuya
Address:1-83 5-Chome Higashihara, Zama-city, Kanagawa-Pref. Japan
Email:kazuya-oono443@morinagamilk.co.jp
Phone:81462523067

Subject:

Subject ID:SU002239
Subject Type:Mammal
Subject Species:Mus musculus
Taxonomy ID:10090
Genotype Strain:AppNL-G-F or wild type mice
Age Or Age Range:7 months old
Gender:Male and female
Animal Animal Supplier:RIKEN Center for Brain Science
Animal Light Cycle:12 hours light and dark cycle

Factors:

Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Model Intervention
SA206357AT-1Alzheimer’s disease model B. breve MCC1274
SA206358AT-2Alzheimer’s disease model B. breve MCC1274
SA206359AT-3Alzheimer’s disease model B. breve MCC1274
SA206360AT-4Alzheimer’s disease model B. breve MCC1274
SA206361AC-3Alzheimer’s disease model Saline
SA206362AC-4Alzheimer’s disease model Saline
SA206363AC-2Alzheimer’s disease model Saline
SA206364AC-1Alzheimer’s disease model Saline
SA206365WT-1Wild type B. breve MCC1274
SA206366WT-3Wild type B. breve MCC1274
SA206367WT-2Wild type B. breve MCC1274
SA206368WT-4Wild type B. breve MCC1274
SA206369WC-2Wild type Saline
SA206370WC-3Wild type Saline
SA206371WC-4Wild type Saline
SA206372WC-1Wild type Saline
Showing results 1 to 16 of 16

Collection:

Collection ID:CO002232
Collection Summary:Plasma samples were obtained from AD-like model and wild-type mice orally administered B. breve MCC1274 or saline for 4 months.
Sample Type:Blood (plasma)
Storage Conditions:-80℃

Treatment:

Treatment ID:TR002251
Treatment Summary:Three-month-old AppNL-G-F and wild type mice were randomly assigned to a vehicle group and a probiotic group. The vehicle group received saline, and the probiotic group received B. breve MCC1274 (1 × 10^9 cfu/200 μl saline/mouse) orally 5 times a week for 4 months.
Treatment Compound:Bifidobacterium breve MCC1274
Treatment Route:oral administration
Treatment Dosevolume:1 × 10^9 cfu/200 μl saline
Treatment Vehicle:saline

Sample Preparation:

Sampleprep ID:SP002245
Sampleprep Summary:For CE-FTMS, 40 µL of plasma was added to 160 µL of methanol containing internal standards at 0°C, 120 µL of Milli-Q water was added and mixed thoroughly, and 240 µL of this mixture was added to a Millipore 5 kDa cutoff filter (ULTRAFREE MC PLHCC, HMT) at 9100 × g for 120 min at 4°C to remove macromolecules. The filtrate was evaporated to dryness under vacuum, dissolved in 40 µL Milli-Q water, and donated to HMT's ω Scan package using capillary electrophoresis Fourier transform mass spectrometry (CE-FTMS).For LC-TOFMS, 80 µL of plasma was added to 240 µL of 1% formic acid/acetonitrile containing internal standards at 0ºC. The mixture was centrifuged at 2,300 x g, 4ºC for 5 min, then centrifuged at 2,300 x g, 4ºC for 5 min, followed by centrifugation of a hybrid SPE phospholipid cartridge (30 mg/mL of hybrid SPE-phospholipid, 30 mg/mL of (SUPELCO) and filtered to remove phospholipids. The filtrate was then evaporated to dryness under nitrogen, dissolved in 80 μL of 50% isopropanol (v/v), and metabolomic analysis was performed using liquid chromatography time-of-flight mass spectrometry (LC-TOFMS).

Combined analysis:

Analysis ID AN003526 AN003527
Analysis type MS MS
Chromatography type Normal phase Reversed phase
Chromatography system Agilent 1260 Agilent 1200
Column fused silica capillary (50 μm i.d. × 80 cm total length; Polymicro Technologies, Inc., Phoenix, AZ) ODS
MS Type ESI ESI
MS instrument type Orbitrap Triple TOF
MS instrument name Thermo Q Exactive Plus Orbitrap Agilent 6210 TOF
Ion Mode UNSPECIFIED UNSPECIFIED
Units peak area peak area

Chromatography:

Chromatography ID:CH002604
Instrument Name:Agilent 1260
Column Name:fused silica capillary (50 μm i.d. × 80 cm total length; Polymicro Technologies, Inc., Phoenix, AZ)
Internal Standard:H3304-1002, Human Metabolome Technologies, Inc. (HMT), Tsuruoka, Yamagata, Japan
Solvent A:commercial electrophoresis buffer (H3301-1001; I3302-1023 for cation; anion analyses, respectively, HMT)
Chromatography Type:Normal phase
  
Chromatography ID:CH002605
Instrument Name:Agilent 1200
Column Name:ODS
Internal Standard:H3304-1002, Human Metabolome Technologies, Inc. (HMT), Tsuruoka, Yamagata, Japan
Chromatography Type:Reversed phase

MS:

MS ID:MS003284
Analysis ID:AN003526
Instrument Name:Thermo Q Exactive Plus Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:The spectrometer was scanned from m/z 60 to 900 in positive mode, and from m/z 70 to 1,050 in negative mode
Ion Mode:UNSPECIFIED
  
MS ID:MS003285
Analysis ID:AN003527
Instrument Name:Agilent 6210 TOF
Instrument Type:Triple TOF
MS Type:ESI
MS Comments:The spectrometer was scanned from m/z 50 to 1,000 and peaks were extracted using MasterHands, automatic integration software (Keio University, Tsuruoka, Yamagata, Japan)
Ion Mode:UNSPECIFIED
  logo